Precision Testing Shifts Management for Barrett's Esophagus Patients

Published in the journal Foregut, the research examined 30 patients at the Keck Medical Center of USC. While all participants initially shared a diagnosis of non-dysplastic Barrett's esophagus, the TissueCypher test successfully stratified these individuals into distinct risk categories. The test classified 17% of the cohort as intermediate or high risk for progression to high-grade dysplasia or esophageal adenocarcinoma, while 83% were identified as low risk.

These findings translated into tangible changes in clinical practice. Physicians escalated care for all patients flagged as intermediate or high risk, opting for endoscopic eradication therapy or more frequent surveillance. Conversely, for 84% of those classified as low risk, clinicians were able to de-escalate treatment by extending surveillance intervals. According to study author Dr. Caitlin C. Houghton, the results provide a mechanism to tailor care to individual risk, potentially avoiding unnecessary procedures for low-risk patients while ensuring earlier intervention for those at higher risk. Overall, the test either altered management recommendations or bolstered physician confidence in 97% of the cases reviewed.